Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy (Q28235277)

3

Upulie

Divisekera

1 reference

19 October 2023

Shin Foong Ngiow

4

Shin Foong

Ngiow

1 reference

19 October 2023

Helene Duret

5

Helene

Duret

1 reference

19 October 2023

Michele W Teng

7

Michele W

Proceedings of the National Academy of Sciences of the United States of America

Teng

1 reference

19 October 2023

language of work or name

English

0 references

publication date

26 April 2011

0 references

published in

0 references

volume

108

0 references

page(s)

7142-7

0 references

issue

17

0 references

cites work

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Trastuzumab--mechanism of action and use in clinical practice

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Combination antibody-based cancer immunotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Eradication of established tumors in mice by a combination antibody-based therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3084100

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

2 June 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1016569108

Adaptive immunity maintains occult cancer in an equilibrium state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1016569108

Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1016569108

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1016569108

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1016569108

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1016569108

Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells

21 January 2018

1 reference

12 December 2020

Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy

1 reference

12 December 2020

1 reference

12 December 2020

Perforin and Granzymes Have Distinct Roles in Defensive Immunity and Immunopathology

1 reference

12 December 2020

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

12 December 2020

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells

1 reference

12 December 2020

Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer

1 reference

12 December 2020

Type I IFN contributes to NK cell homeostasis, activation, and antitumor function

1 reference

12 December 2020

Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.1016569108

1 reference

2063540

ADS bibcode

2011PNAS..108.7142S

0 references

2063540

1 reference

1 reference

1 reference